Stivarga (regorafenib) — United Healthcare

Initial criteria

• Diagnosis of advanced or metastatic colorectal cancer
• History of failure, contraindication, or intolerance to ALL of the following: Oxaliplatin-based chemotherapy AND Irinotecan-based chemotherapy AND Anti-VEGF-based chemotherapy
• One of the following: Tumor is RAS mutant-type OR (Tumor is RAS wild-type AND history of failure, contraindication, or intolerance to anti-EGFR therapy [e.g., Erbitux (cetuximab), Vectibix (panitumumab)])

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Stivarga therapy

Approval duration

12 months